← Back to Home

Beyond Symptom Relief, the Gut Must Heal Too: VERDICT Trial Supports Deeper Treatment Targets in Ulcerative Colitis

Targeting symptomatic, endoscopic, and histologic remission together may delay complications of ulcerative colitis. However, the key findings come from patients who achieved their targets; the benefit of additionally pursuing microscopic healing beyond endoscopic remission remains unestablished.

By SURL BioNews

For patients with ulcerative colitis, how far should treatment go once symptoms subside? The VERDICT trial offers new clues: among patients who achieved their assigned treatment targets, those who attained symptomatic, endoscopic, and histologic remission had a longer time to their first disease-related complication than those whose target was symptomatic remission alone. This extends the assessment of treatment beyond how patients feel day to day to the recovery of intestinal tissue.

Takeda announced the results of this phase 4 randomized trial on October 19. The data were presented at United European Gastroenterology Week (UEG Week) and published in the *United European Gastroenterology Journal*. The study enrolled 672 adults with moderately to severely active ulcerative colitis, with targets of corticosteroid-free symptomatic remission, symptomatic plus endoscopic remission, or the addition of histologic remission. The final target is termed “disease clearance,” meaning remission at all three levels, rather than a cure. Treatment followed a strategy based on intravenous vedolizumab (brand name ENTYVIO), with protocol-directed adjustments when targets were not achieved.

By week 48, a total of 400 patients had achieved their assigned targets. According to Takeda’s announcement and HCPLive’s reporting, among these patients, the hazard ratio for a first disease-related complication in the disease clearance group versus the symptomatic remission group was 0.33 (95% confidence interval 0.17 to 0.67; P = 0.0014), with follow-up extending to 80 weeks after target achievement. This corresponds to an approximately 67% lower instantaneous risk during follow-up; it cannot be interpreted as 67 fewer complications per 100 patients.

There are important limits to the applicability of this finding. The primary comparison focused on patients who achieved their targets, rather than all randomized patients; approximately 40% of participants had not achieved their assigned targets by week 48. Target achievement rates declined as the targets became more stringent, at 74.1%, 56.3%, and 52.1%, respectively. Thus, the data support an association between deeper remission and better subsequent outcomes, but do not directly establish that adopting a more stringent treatment strategy would deliver the same magnitude of benefit for all patients.

Whether microscopic healing provides additional benefits also remains unclear. There was no significant difference in time to first complication between the symptomatic plus endoscopic remission group and the disease clearance group (hazard ratio 1.10; 95% confidence interval 0.45 to 2.69; P = 0.8023). Among patients in the former group who achieved their target, more than 80% had also achieved histologic remission at week 48, creating overlap in the groups’ actual disease states. This neither proves that the two targets are equivalent nor establishes the clinical benefit of additionally pursuing histologic remission.

The trial recorded 51 disease-related complications, most commonly the use of rescue therapy. This composite endpoint also included hospitalization, colectomy, and other events, so the overall difference cannot be directly interpreted as an equivalent reduction in surgical risk. Benzinga’s French-language reporting also noted similar adverse event rates across the three groups, with no new safety signals identified through week 96. This provides safety information during treatment adjustments, although it remains limited by the duration of follow-up and the study’s size.

The study also used proteomic and transcriptomic analyses to explore molecular changes in biologic-naive patients who achieved disease clearance at week 16, identifying pathway signals involving inflammation, mucosal homeostasis, and tissue repair. These exploratory findings do not yet establish mechanisms of repair, but they add biological clues to the clinical observations. VERDICT’s central contribution is to provide prospective trial evidence for discussing how thoroughly the gut should heal; more complete evidence is still needed to translate these targets into treatment decisions suited to different patients.

References

  1. Takeda
  2. HCPLive
  3. Benzinga France